Skip to content
ChickenStockChickenStock
ResearchADMA
Adma Biologics logo

Adma Biologics (ADMA) stock

NASDAQ

$13.69+3.40%(+0.45)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

16.60x

P/B

6.92x

P/S

5.86x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 5.2% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

4 SEC filings
  • Grossman Adam SPresident and CEO · Nov 5, 2026Open-market sale147,000 shares · $1.8M
    Avg. price $12
    Show 2 price lots
    • 105,000 shares × $12$1.3M
    • 42,000 shares × $12$504K
  • Grossman Adam SPresident and CEO · Nov 5, 2026Option exercise105,000 shares · $567K
    Avg. price $5.42,217,777 shares held after
  • Kestenberg-Messina Kaitlin M.COO and SVP, Compliance · Jul 24, 2026Shares withheld for taxes3,177 shares · $27K
    Avg. price $8.37443,061 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Adma Biologics (ADMA) stock information

NASDAQ

Adma Biologics (ADMA) is listed on NASDAQ. Its market capitalization is about $3B. On trailing-twelve-month earnings the P/E ratio is 16.6, and the P/B ratio is 6.92. Return on equity is 41.7%. These figures are computed in-house from official filings and are reference information only.

Adma Biologics — frequently asked questions

What is the P/E ratio of Adma Biologics (ADMA)?
On a trailing-twelve-month basis, ADMA trades at a P/E ratio of 16.6. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Adma Biologics?
ADMA has a market capitalization of about $3B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.